Population pharmacokinetics of amodiaquine and piperaquine in African pregnant women with uncomplicated Plasmodium falciparum infections

Author:

Ding Junjie12,Hoglund Richard M.12,Tagbor Harry3,Tinto Halidou4,Valéa Innocent4,Mwapasa Victor5,Kalilani‐Phiri Linda5,Van Geertruyden Jean‐Pierre6,Nambozi Michael7,Mulenga Modest7,Hachizovu Sebastian7,Ravinetto Raffaella89,D'Alessandro Umberto10,Tarning Joel1211ORCID

Affiliation:

1. Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine Mahidol University Bangkok Thailand

2. Centre for Tropical Medicine and Global Health, Nuffield Department of Clinical Medicine University of Oxford Oxford UK

3. University of Health and Allied Sciences Ho Ghana

4. Clinical Trial Unit Nanoro Nanoro Burkina Faso

5. Department of Community and Environmental Health, Kamuzu University of Health Sciences Blantyre Malawi

6. Global Health Institute University of Antwerp Antwerp Belgium

7. The Tropical Diseases Research Center Ndola Zambia

8. Public Health Department Institute of Tropical Medicine Antwerp Belgium

9. School of Public Health University of the Western Cape Cape Town South Africa

10. MRC Unit The Gambia at the London School of Hygiene and Tropical Medicine Fajara Gambia

11. The WorldWide Antimalarial Resistance Network Oxford UK

Abstract

AbstractArtemisinin‐based combination therapy (ACT) is the first‐line recommended treatment for uncomplicated malaria. Pharmacokinetic (PK) properties in pregnant women are often based on small studies and need to be confirmed and validated in larger pregnant patient populations. This study aimed to evaluate the PK properties of amodiaquine and its active metabolite, desethylamodiaquine, and piperaquine in women in their second and third trimester of pregnancy with uncomplicated P. falciparum infections. Eligible pregnant women received either artesunate‐amodiaquine (200/540 mg daily, n = 771) or dihydroartemisinin‐piperaquine (40/960 mg daily, n = 755) for 3 days (NCT00852423). Population PK properties were evaluated using nonlinear mixed‐effects modeling, and effect of gestational age and trimester was evaluated as covariates. 1071 amodiaquine and 1087 desethylamodiaquine plasma concentrations, and 976 piperaquine plasma concentrations, were included in the population PK analysis. Amodiaquine concentrations were described accurately with a one‐compartment disposition model followed by a two‐compartment disposition model of desethylamodiaquine. The relative bioavailability of amodiaquine increased with gestational age (1.25% per week). The predicted exposure to desethylamodiaquine was 2.8%–32.2% higher in pregnant women than that reported in non‐pregnant women, while day 7 concentrations were comparable. Piperaquine concentrations were adequately described by a three‐compartment disposition model. Neither gestational age nor trimester had significant impact on the PK of piperaquine. The predicted exposure and day 7 concentrations of piperaquine were similar to that reported in non‐pregnant women. In conclusion, the exposure to desethylamodiaquine and piperaquine was similar to that in non‐pregnant women. Dose adjustment is not warranted for women in their second and their trimester of pregnancy.

Publisher

Wiley

Reference38 articles.

1. WHO.World malaria report 2022.2022https://www.who.int/teams/global‐malaria‐programme/reports/world‐malaria‐report‐2022

2. An analysis of malaria in pregnancy in Africa;Brabin BJ;Bull World Health Organ,1983

3. Malaria and immunity during pregnancy and postpartum: a tale of two species;McLean AR;Parasitology,2015

4. WHO.Intermittent preventive treatment in pregnancy (IPTp).2017http://www.who.int/malaria/areas/preventive_therapies/pregnancy/en/

5. Malaria;White NJ;Lancet,2014

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3